In vivo activation of STAT3 in cutaneous T-cell lymphoma.: Evidence for an antiapoptotic function of STAT3

被引:139
作者
Sommer, VH
Clemmensen, OJ
Nielsen, O
Wasik, M
Lovato, P
Brender, C
Eriksen, KW
Woetmann, A
Kaestel, CG
Nissen, MH
Ropke, C
Skov, S
Odum, N
机构
[1] Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, DK-2200 Copenhagen N, Denmark
[2] Odense Univ Hosp, Dept Pathol, DK-5000 Odense, Denmark
[3] Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[4] Univ Copenhagen, Copenhagen, Denmark
关键词
CTCL; STAT3; neoplastic transformation; in vivo; apoptosis;
D O I
10.1038/sj.leu.2403385
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A characteristic feature of neoplastic transformation is a perpetual activation of oncogenic proteins. Here, we studied signal transducers and activators of transcription ( STAT) in patients with mycosis fungoides (MF)/cutaneous T-cell lymphoma ( CTCL). Malignant lymphocytes in dermal infiltrates of CTCL tumors showed frequent and intense nuclear staining with anti-PY-STAT3 antibody, indicating a constitutive activation of STAT3 in vivo in tumor stages. In contrast, only sporadic and faint staining was observed in indolent lesions of patch and plaque stages of MF. Moreover, neoplastic lymphocytes in the epidermal Pautrier abscesses associated with early stages of MF did not express activated STAT3. To address the role of STAT3 in survival/ apoptosis, CTCL tumor cells from an advanced skin tumor were transfected with either wild-type STAT3 (STAT3wt) or dominant-negative STAT3 (STAT3D). Forced inducible expression of STAT3D triggered a significant increase in tumor cells undergoing apoptosis, whereas forced expression of STAT3wt or empty vector had no effect. In conclusion, a profound in vivo activation of STAT3 is observed in MF tumors but not in the early stages of MF. Moreover, STAT3 protects tumor cells from apoptosis in vitro. Taken together, these findings suggest that STAT3 is a malignancy factor in CTCL.
引用
收藏
页码:1288 / 1295
页数:8
相关论文
共 33 条
[1]  
Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456
[2]   Signal transducer and activator of transcription proteins in leukemias [J].
Benekli, M ;
Baer, MR ;
Baumann, H ;
Wetzler, M .
BLOOD, 2003, 101 (08) :2940-2954
[3]   Interferon-alpha induces transient suppressors of cytokine signalling expression in human T cells [J].
Brender, C ;
Nielsen, M ;
Röpke, C ;
Nissen, MH ;
Svejgaard, A ;
Billestrup, N ;
Geisler, C ;
Odum, N .
EXPERIMENTAL AND CLINICAL IMMUNOGENETICS, 2001, 18 (02) :80-85
[4]   STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma [J].
Brender, C ;
Nielsen, M ;
Kaltoft, K ;
Mikkelsen, G ;
Zhang, Q ;
Wasik, M ;
Billestrup, N ;
Odum, N .
BLOOD, 2001, 97 (04) :1056-1062
[5]   Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development [J].
Bromberg, J .
BREAST CANCER RESEARCH, 2000, 2 (02) :86-90
[6]   Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[7]   Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells [J].
Catlett-Falcone, R ;
Landowski, TH ;
Oshiro, MM ;
Turkson, J ;
Levitzki, A ;
Savino, R ;
Ciliberto, G ;
Moscinski, L ;
Fernández-Luna, JL ;
Nuñez, G ;
Dalton, WS ;
Jove, R .
IMMUNITY, 1999, 10 (01) :105-115
[8]   Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3 [J].
Chapman, RS ;
Lourenco, PC ;
Tonner, E ;
Elint, DJ ;
Selbert, S ;
Takeda, K ;
Akira, S ;
Clarke, AR ;
Watson, CJ .
GENES & DEVELOPMENT, 1999, 13 (19) :2604-2616
[9]   Mycosis fungoides and Sezary syndrome [J].
Diamandidou, E ;
Cohen, PR ;
Kurzrock, R .
BLOOD, 1996, 88 (07) :2385-2409
[10]   Constitutive STAT3-activation in Sezary syndrome:: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells [J].
Eriksen, KW ;
Kaltoft, K ;
Mikkelsen, G ;
Nielsen, M ;
Zhang, Q ;
Geisler, C ;
Nissen, MH ;
Röpke, C ;
Wasik, MA ;
Odum, N .
LEUKEMIA, 2001, 15 (05) :787-793